Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2008 Jul;7(7):1900–1908. doi: 10.1158/1535-7163.MCT-08-0012

Figure 5. Combination NDGA plus trastuzumab inhibits proliferation of trastuzumab-refractory breast cancer cells.

Figure 5

Figure 5

Figure 5

Figure 5

(A) SK-parental, (B) SK-HRp2, (C) BT-parental, and (D) BT-HRp3 cells were treated with NDGA (40 μM), trastuzumab (20 μg/mL), or a combination of both drugs for 6 d, at which point cell proliferation was measured by standard colorimetric MTS assay. Experiments were done at least twice, in 6 replicates per group each time. Cell proliferation is expressed as a percentage of untreated cells per line, with error bars representing standard deviation between replicates; values are shown above each bar. The combination of NDGA plus trastuzumab inhibited cell proliferation to a greater degree than either agent alone, suggesting that NDGA partially restores trastuzumab efficacy to trastuzumab-refractory breast cancer cells.